Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

CPX-351 ((Cytarabine:Daunorubicin) Liposome Injection, (Vyxeos)) Does Not Prolong Qtcf Intervals, Requires No Dose Adjustment for Impaired Renal Function and Induces High Rates of Complete Remission in Acute Myeloid Leukemia

Tara L. Lin, MD, Laura F. Newell, MD, Robert K. Stuart, MD, Laura C. Michaelis, MD, Stephen E. Rubenstein, MD, Helen S. Pentikis, PhD, Timothy Callahan, PhD, Donna Alvarez, Lawrence D. Mayer, PhD, Arthur C. Louie, MD

Blood (2015) 126 (23): 2510.

https://doi.org/10.1182/blood.V126.23.2510.2510

Published: 2015

Journal Articles

Quantitative Whole Body Autoradiography (QWBA) Analysis Reveals That CPX-351 Shifts the Exposure of Cytarabine (Cyt) and Daunorubicin (Daun) Away from Many Tissues While Providing Prolonged Exposure to Cytotoxic Drug Concentrations in the Bone Marrow Compared to Conventional Free Drug Administration

Lawrence D Mayer, PhD, Nicole Sadowski, Paul Tardi, PhD, Xiaowei Xie, PhD, Donna Cabral-Lilly, PhD, Dennis Heller, PhD

Blood (2014) 124 (21): 3740.

https://doi.org/10.1182/blood.V124.21.3740.3740

Published: 2014

Journal Articles

CPX-351 Markedly Reduces Renal and Hepatic Clearance Rates for Cytarabine (Cyt) and Daunorubicin (Daun) in Rats with an Associated Decrease in Excretory and Metabolic Burden Despite Providing Dramatic Increases in Systemic Drug Exposure Compared to Conventional Cyt+Daun

Lawrence D Mayer, PhD, Jeffrey Fulton, Heasook Kim-Kang, Yijun Yi, Peter Wang, Paul Tardi, PhD, Xiaowei Xi, Dennis Heller, PhD

Blood (2014) 124 (21): 2305.

https://doi.org/10.1182/blood.V124.21.2305.2305

Published: 2014

Journal Articles

Improved Selectivity against Acute Myeloid Leukemia (AML) Blasts Over Normal Hematopoietic Progenitors for Cytarabine: Daunorubicin Delivered as CPX-351 Liposome Injection.

Peter Kim, Gitte Gerhard, Troy O. Harasym, PhD, Wahseng Lim, PhD, Natalia Zisman, Lawrence D Mayer, PhD, Donna E. Hogge, MD, PhD

Blood (2009) 114 (22): 2071.

https://doi.org/10.1182/blood.V114.22.2071.2071

Published: 2009

Journal Articles

Phase I Study of a Liposomal Carrier (CPX-351) Containing a Synergistic, Fixed Molar Ratio of Cytarabine (Ara-C) and Daunorubicin (DNR) in Advanced Leukemias

Eric J. Feldman, MD, Jeffrey Lancet, MD, Jonathan E. Kolitz, MD, Ellen Ritchie, MD, Alan F. List, MD, Ekatherine Asatiani, MD, Tania J Curcio, Michelle Burton, RN, Marge Fricano, BSN, Christine Swenson, Lawrence D Mayer, PhD, Arthur C. Louie, MD

Blood (2008) 112 (11): 2984.

https://doi.org/10.1182/blood.V112.11.2984.2984

Published: 2008

NARROW

CPX-351 ((Cytarabine:Daunorubicin) Liposome Injection, (Vyxeos)) Does Not Prolong Qtcf Intervals, Requires No Dose Adjustment for Impaired Renal Function and Induces High Rates of Complete Remission in Acute Myeloid Leukemia

Quantitative Whole Body Autoradiography (QWBA) Analysis Reveals That CPX-351 Shifts the Exposure of Cytarabine (Cyt) and Daunorubicin (Daun) Away from Many Tissues While Providing Prolonged Exposure to Cytotoxic Drug Concentrations in the Bone Marrow Compared to Conventional Free Drug Administration

CPX-351 Markedly Reduces Renal and Hepatic Clearance Rates for Cytarabine (Cyt) and Daunorubicin (Daun) in Rats with an Associated Decrease in Excretory and Metabolic Burden Despite Providing Dramatic Increases in Systemic Drug Exposure Compared to Conventional Cyt+Daun

Improved Selectivity against Acute Myeloid Leukemia (AML) Blasts Over Normal Hematopoietic Progenitors for Cytarabine: Daunorubicin Delivered as CPX-351 Liposome Injection.

Phase I Study of a Liposomal Carrier (CPX-351) Containing a Synergistic, Fixed Molar Ratio of Cytarabine (Ara-C) and Daunorubicin (DNR) in Advanced Leukemias

Email alerts

ASH Publications

American Society of Hematology

CPX-351 ((Cytarabine:Daunorubicin) Liposome Injection, (Vyxeos)) Does Not Prolong Qtcf Intervals, Requires No Dose Adjustment for Impaired Renal Function and Induces High Rates of Complete Remission in Acute Myeloid Leukemia

CPX-351 Markedly Reduces Renal and Hepatic Clearance Rates for Cytarabine (Cyt) and Daunorubicin (Daun) in Rats with an Associated Decrease in Excretory and Metabolic Burden Despite Providing Dramatic Increases in Systemic Drug Exposure Compared to Conventional Cyt+Daun

Improved Selectivity against Acute Myeloid Leukemia (AML) Blasts Over Normal Hematopoietic Progenitors for Cytarabine: Daunorubicin Delivered as CPX-351 Liposome Injection.

Phase I Study of a Liposomal Carrier (CPX-351) Containing a Synergistic, Fixed Molar Ratio of Cytarabine (Ara-C) and Daunorubicin (DNR) in Advanced Leukemias

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only